.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Citi
Argus Health
Novartis
Farmers Insurance
Chinese Patent Office
QuintilesIMS
McKinsey
Fish and Richardson
Johnson and Johnson

Generated: June 28, 2017

DrugPatentWatch Database Preview

LAMISIL AT Drug Profile

« Back to Dashboard

Which patents cover Lamisil At, and when can generic versions of Lamisil At launch?

Lamisil At is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in LAMISIL AT is terbinafine. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the terbinafine profile page.

Summary for Tradename: LAMISIL AT

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list2
Bulk Api Vendors: see list57
Clinical Trials: see list12
Patent Applications: see list5,481
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LAMISIL AT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
LAMISIL AT
terbinafine hydrochloride
SOLUTION;TOPICAL021124-001Mar 17, 2000OTCYesYes► Subscribe► Subscribe
Novartis
LAMISIL AT
terbinafine hydrochloride
SPRAY;TOPICAL021124-002Mar 17, 2000OTCYesYes► Subscribe► Subscribe
Novartis
LAMISIL AT
terbinafine
GEL;TOPICAL021958-001Jul 24, 2006OTCYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LAMISIL AT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
LAMISIL AT
terbinafine hydrochloride
SOLUTION;TOPICAL021124-001Mar 17, 20006,121,314*PED► Subscribe
Novartis
LAMISIL AT
terbinafine
GEL;TOPICAL021958-001Jul 24, 20066,121,314► Subscribe
Novartis
LAMISIL AT
terbinafine hydrochloride
SPRAY;TOPICAL021124-002Mar 17, 20004,755,534*PED► Subscribe
Novartis
LAMISIL AT
terbinafine hydrochloride
SOLUTION;TOPICAL021124-001Mar 17, 20004,680,291► Subscribe
Novartis
LAMISIL AT
terbinafine hydrochloride
SOLUTION;TOPICAL021124-001Mar 17, 20005,681,849*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Moodys
Chubb
Dow
UBS
Federal Trade Commission
Daiichi Sankyo
Colorcon
Mallinckrodt
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot